June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Development and validation of a mobility test for Inherited Retinal Disease in real and virtual conditions - preliminary results.
Author Affiliations & Notes
  • Colas Nils Authié
    Streetlab - Institut de la Vision, Paris, IDF, France
  • Mylène Poujade
    Sorbonne Universités, UPMC Université Paris 06, INSERM U968, CNRS UMR7210, Institut de la Vision, Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC 1423, Paris, IDF, France
    Department of Ophthalmology,, School of Medicine, University of Pittsburgh, Pittsburg, Pennsylvania, Pittsburgh, Pennsylvania, United States
  • Alireza Talebi
    Streetlab - Institut de la Vision, Paris, IDF, France
    Sorbonne Universités, UPMC Université Paris 06, INSERM U968, CNRS UMR7210, Institut de la Vision, Paris, IDF, France
  • Alexis Defer
    Streetlab - Institut de la Vision, Paris, IDF, France
  • Ariel Zenouda
    Streetlab - Institut de la Vision, Paris, IDF, France
  • Cecilia Coen
    Streetlab - Institut de la Vision, Paris, IDF, France
  • Yihan Zhang
    Streetlab - Institut de la Vision, Paris, IDF, France
  • Jose Alain Sahel
    Sorbonne Universités, UPMC Université Paris 06, INSERM U968, CNRS UMR7210, Institut de la Vision, Paris, IDF, France
    Department of Ophthalmology,, School of Medicine, University of Pittsburgh, Pittsburg, Pennsylvania, Pittsburgh, Pennsylvania, United States
  • Saddek Mohand-Said
    Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC 1423, Paris, IDF, France
  • Philippe Chaumet-Riffaud
    Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, DHU Sight Restore, INSERM-DHOS CIC 1423, Paris, IDF, France
  • Isabelle S Audo
    Sorbonne Universités, UPMC Université Paris 06, INSERM U968, CNRS UMR7210, Institut de la Vision, Paris, IDF, France
    Centre Hospitalier National d’Ophtalmologie des Quinze-Vingts, DHU Sight Restore, Centre de Référence Maladies Rares REFERET, INSERM-DHOS CIC 1423, Paris, IDF, France
  • Footnotes
    Commercial Relationships   Colas Authié None; Mylène Poujade None; Alireza Talebi None; Alexis Defer None; Ariel Zenouda None; Cecilia Coen None; Yihan Zhang None; Jose Sahel Pixium Vision, GenSight Biologics, Sparing Vision, Prophesee, Chronolife, Tilak Healthcare, Vegavect, Newsight, Replay Therapeutics, SharpEye, Code I (Personal Financial Interest), GenSight Biologics, Code P (Patent); Saddek Mohand-Said None; Philippe Chaumet-Riffaud None; Isabelle Audo None
  • Footnotes
    Support  This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 861423 (enTRAIN Vision) and a support of the IHU FOReSIGHT Grant ANR-18-IAHU-01
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 715 – F0443. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Colas Nils Authié, Mylène Poujade, Alireza Talebi, Alexis Defer, Ariel Zenouda, Cecilia Coen, Yihan Zhang, Jose Alain Sahel, Saddek Mohand-Said, Philippe Chaumet-Riffaud, Isabelle S Audo; Development and validation of a mobility test for Inherited Retinal Disease in real and virtual conditions - preliminary results.. Invest. Ophthalmol. Vis. Sci. 2022;63(7):715 – F0443.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Although Inherited Retinal Disease (IRD) are well characterized in terms of anatomical and functional progression, their impact on patients' daily lives is often poorly understood and lacks standardized measures as performance-based outcomes (PerfO) evaluating the performance in daily-life tasks, such as orientation and mobility. We developed a new mobility test in real (IRL) and virtual (VR) conditions and performed a prospective, interventional non-invasive, longitudinal study (test-retest) to compare the performance of IRD patients and healthy participants in both conditions (IRL v.s. VR).

Methods : Fifteen retinitis pigmentosa patients and 15 age-matched healthy participants had to walk through a maze either physically presented (IRL) or displayed in a virtual reality headset (HTC Vive Pro Eye). In multiple light level conditions (between 1 Lux and 400 Lux in IRL), participants were instructed to step over two steps, pass under two flags, avoid a cone and two high obstacles, avoid a dead-end, and finally reach an end goal. Trial duration and errors were automatically recorded in VR condition. In IRL condition, errors were live coded by an experimenter and recorded by a different experimenter after the session. We computed a performance score taking in account duration and errors.

Results : Preliminary results indicate a good construct validity (discrimination between groups, ROC area>.9), a very good agreement of the performance score between sessions (ICC>.95) and between VR and IRL conditions (ICC>.9), and a good content validity (correlation with a visual score .41 and .65). Moreover, test duration was acceptable for 95% of participants (both conditions) and the VR experience was rated as enjoyable for 73% of participants. 78% of RP participants felt that the VR test was representative of their difficulties in daily life.

Conclusions : We have designed a locomotion test, both in real (IRL) and virtual (VR) conditions, that has excellent reproducibility and high agreement between both conditions. Additional data are awaited to confirm these results, and measure sensitivity to change which will determine its interest in monitoring the progression of a retinal disease and assessing the efficacy of new treatments.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×